Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENVB NYSE:IBIO OTCMKTS:NXEN NASDAQ:PWUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$0.63-2.6%$1.16$0.62▼$8.33$2.05M0.581.15 million shs474,780 shsIBIOiBio$0.87+3.2%$0.76$0.56▼$6.89$17.10M0.861.46 million shs311,702 shsNXENNexien Biopharma$0.01-55.8%$0.01$0.00▼$0.05$403K-0.8715,396 shs34,697 shsPWUPPowerUp Acquisition$0.45+8.1%$0.44$8.05▼$15.80$3.46M0.053,464 shs1.59 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences-29.30%-29.75%-45.64%-48.66%-91.45%IBIOiBio-2.48%-4.51%+13.48%-6.34%-55.40%NXENNexien Biopharma+8.40%+8.40%+126.32%+38.71%-25.86%PWUPPowerUp Acquisition+8.11%+3.44%+24.04%+40.08%-96.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$0.63-2.6%$1.16$0.62▼$8.33$2.05M0.581.15 million shs474,780 shsIBIOiBio$0.87+3.2%$0.76$0.56▼$6.89$17.10M0.861.46 million shs311,702 shsNXENNexien Biopharma$0.01-55.8%$0.01$0.00▼$0.05$403K-0.8715,396 shs34,697 shsPWUPPowerUp Acquisition$0.45+8.1%$0.44$8.05▼$15.80$3.46M0.053,464 shs1.59 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences-29.30%-29.75%-45.64%-48.66%-91.45%IBIOiBio-2.48%-4.51%+13.48%-6.34%-55.40%NXENNexien Biopharma+8.40%+8.40%+126.32%+38.71%-25.86%PWUPPowerUp Acquisition+8.11%+3.44%+24.04%+40.08%-96.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENVBEnveric Biosciences 3.00Buy$10.001,487.30% UpsideIBIOiBio 3.00Buy$5.00474.71% UpsideNXENNexien Biopharma 0.00N/AN/AN/APWUPPowerUp Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NXEN, PWUP, IBIO, and ENVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AIBIOiBio$400K42.75N/AN/A$1.41 per share0.62NXENNexien BiopharmaN/AN/AN/AN/A($0.01) per shareN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)IBIOiBio-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/ANXENNexien Biopharma-$240KN/A0.00∞N/AN/AN/A-4,015.59%N/APWUPPowerUp AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest NXEN, PWUP, IBIO, and ENVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENVBEnveric BiosciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENVBEnveric BiosciencesN/A2.422.42IBIOiBio0.051.761.76NXENNexien BiopharmaN/A0.020.02PWUPPowerUp AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENVBEnveric Biosciences13.82%IBIOiBio7.90%NXENNexien BiopharmaN/APWUPPowerUp Acquisition19.17%Insider OwnershipCompanyInsider OwnershipENVBEnveric Biosciences1.10%IBIOiBio0.58%NXENNexien Biopharma30.60%PWUPPowerUp Acquisition48.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENVBEnveric Biosciences203.25 million3.21 millionNot OptionableIBIOiBio10019.66 million9.82 millionN/ANXENNexien Biopharma470.77 million49.12 millionNot OptionablePWUPPowerUp AcquisitionN/A7.77 million4.04 millionNot OptionableNXEN, PWUP, IBIO, and ENVB HeadlinesRecent News About These CompaniesAspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | finanznachrichten.deAspire Biopharma, PowerUp Acquisition complete business combinationFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma announces public listing on NasdaqFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | accessnewswire.comAAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 19, 2025 | accessnewswire.comA(PWUP) Technical Pivots with Risk ControlsFebruary 13, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp trading resumesFebruary 12, 2025 | markets.businessinsider.comPowerUp Acquisition Corp trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPowerUp Stock Soars to All-Time High of $14.84 Amidst Strong GrowthFebruary 11, 2025 | msn.comPowerUp Acquisition Corp. Approves Merger with Aspire BiopharmaFebruary 11, 2025 | msn.comWhen (PWUP) Moves Investors should ListenFebruary 2, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp. Cl AJanuary 17, 2025 | wsj.comHow to Take Advantage of moves in (PWUP)January 12, 2025 | news.stocktradersdaily.comNPWUP PowerUp Acquisition Corp.December 12, 2024 | seekingalpha.comHow To Trade (PWUP)November 19, 2024 | news.stocktradersdaily.comNWhen the Price of (PWUP) Talks, People ListenOctober 18, 2024 | news.stocktradersdaily.comNSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGROctober 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, PWUP, RVNC, ESGR on Behalf of ShareholdersOctober 8, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP, ESGROctober 7, 2024 | accesswire.comA(PWUPU) Investment AnalysisSeptember 26, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXEN, PWUP, IBIO, and ENVB Company DescriptionsEnveric Biosciences NASDAQ:ENVB$0.63 -0.02 (-2.61%) Closing price 04:00 PM EasternExtended Trading$0.64 +0.01 (+0.79%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.iBio NYSE:IBIO$0.87 +0.03 (+3.22%) Closing price 04:00 PM EasternExtended Trading$0.87 0.00 (0.00%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Nexien Biopharma OTCMKTS:NXEN$0.0057 -0.01 (-55.81%) As of 02:29 PM EasternNexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.PowerUp Acquisition NASDAQ:PWUP$0.45 +0.03 (+8.11%) As of 09/16/2025PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
